The Effects of Diagnostic Definitions in Claims Data on Healthcare Cost Estimates: Evidence from a Large-Scale Panel Data Analysis of Diabetes Care in Japan

Haruhisa Fukuda (), Shunya Ikeda, Takeru Shiroiwa and Takashi Fukuda
Additional contact information
Haruhisa Fukuda: Kyushu University Graduate School of Medical Sciences
Shunya Ikeda: International University of Health and Welfare
Takeru Shiroiwa: National Institute of Public Health
Takashi Fukuda: National Institute of Public Health

PharmacoEconomics, 2016, vol. 34, issue 10, No 5, 1005-1014

Abstract: Abstract Background Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses. Objectives The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates. Research design Monthly panel data analysis of Japanese claims data. Subjects The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013. Measures Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models. Results The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 % confidence interval (CI) 178–181] to US$223 (95 % CI 221–224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 % CI 13,568–13,622), neuropathy/extremity disease with surgery (US$4594; 95 % CI 3979–5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667–3711). Conclusions Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.

Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-016-0402-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:34:y:2016:i:10:d:10.1007_s40273-016-0402-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-016-0402-3

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().